Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies

PHASE2CompletedINTERVENTIONAL
Enrollment

91

Participants

Timeline

Start Date

September 30, 2019

Primary Completion Date

June 30, 2020

Study Completion Date

June 30, 2020

Conditions
Dementia With Lewy Bodies (DLB)
Interventions
DRUG

Neflamapimod

Double-Blind, Placebo-Controlled

Trial Locations (24)

10032

New York Presbyterian Hospital - Columbia University Medical Center, New York

14618

University of Rochester, Rochester

19107

Thomas Jefferson University, Philadelphia

22908

University of Virginia, Charlottesville

23294

National Clinical Research, Inc., Richmond

27599

University of North Carolina, Chapel Hill

33144

Elite Clinical Research, Miami

43210

The Ohio State University, Columbus

44195

Cleveland Clinic, Cleveland

48105

University of Michigan, Ann Arbor

55905

Mayo Clinic, Rochester

66103

University of Kansas Medical Center, Kansas City

80045

University of Colorado, Aurora

89106

Cleveland Clinic - Lou Ruvo Center for Brain Health, Las Vegas

90404

Pacific Neuroscience Institute, Santa Monica

92037

University of California San Diego (UCSD), La Jolla

97210

Summit Research Network, Portland

97239

Oregon Health & Science University, Portland

98007

Northwest Clinical Research Center, Bellevue

98104

University of Washington, Seattle

99202

Inland Northwest Research, Spokane

02129

Massachusetts General Hospital, Charlestown

Unknown

Brain Research Center, 's-Hertogenbosch

Brain Research Center, Amsterdam

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Worldwide Clinical Trials

OTHER

lead

EIP Pharma Inc

INDUSTRY